No Improvement in OS With Atezolizumab in Relapsing TNBC
Adding atezolizumab to chemotherapy in anti-PD-L1-positive TNBC patients who have relapsed did not improve survival, as shown in the IMpassion132 trial. These patients have a poor prognosis, are typically young, and have aggressive disease resistant to standard therapies. Patients treated with capecitabine had better survival rates than those on carboplatin/gemcitabine, suggesting prior therapy may influence…